Imprivata Achieves 51 Percent Single Sign-on Market Share Amongst U.S. Hospitals Using McKesson Paragon or Horizon EMR Systems, According to HIMSS Analytics

Published on:

Lexington, MA, July 30, 2014 -- Imprivata® (NYSE: IMPR), a leading provider of authentication, access management and secure communications solutions for the healthcare industry, today announced that Imprivata OneSign® is the most widely selected single sign-on (SSO) solution amongst U.S. hospitals using McKesson Paragon or Horizon electronic medical records (EMR) systems with a 51 percent market share (an increase of about 11 percent in the last 12 months), according to HIMSS Analytics data. Imprivata will showcase its SSO, authentication and access management solutions as well as Imprivata Cortext®, the secure communications platform for healthcare, in booth #713 at InSight365: 2014 Annual Conference (August 5-8, 2014 in Indianapolis, Ind.).

In addition, Imprivata customer Philip Bierdz, infrastructure manager at Riverside Medical Center (Bourbonnais, Ill.), will deliver a presentation titled “Single Sign-on: Is it Worth the Investment?” (session #3156) on Thursday, August 7 at 9:15 a.m. in room 139. In this session, Bierdz will discuss how Riverside Medical Center uses Imprivata OneSign to enable fast, secure access to its McKesson EMR system and other clinical applications. Bierdz will also walk attendees through the complete process of implementing an SSO solution, from the initial selection to maximizing the benefits. Attendees will gain an understanding of the costs and benefits of SSO applications and also see a live demonstration of Imprivata OneSign.

About Imprivata
Imprivata is a leading provider of authentication and access management solutions for the healthcare industry. Imprivata’s single sign-on, authentication management and secure communications solutions enable fast, secure and more efficient access to healthcare information technology systems to address multiple security challenges and improve provider productivity for better focus on patient care. For more information, please visit http://www.imprivata.com.

Related Content

Christmas ransomware exposed over 300K patient records to dark web
Private equity-backed cardiology group puts cloud-based technology in hands of its cardiologists
AI helps cardiologists deliver personalized healthcare—but there is still plenty of work to do
Indiana hospitals reduce nuisance alerts by 77% with medication decision support software
Leveraging machine learning to rapidly create clinical AI algorithms
How medication reconciliation data consolidation in the EHR enables better patient care

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.